Info

Nanologix is a nano-bio technology company operating in the medical diagnostics and alternative energy fields. The company has been granted 31 patents in those fields. The company’s technology is used to design and market diagnostic test kits for use in early detection of the bacteria present in infectious and noninfectious human diseases such as tuberculosis, pneumonia, HIV/AIDS, cancer, and cystic fibrosis. These patents are licensed or assigned to NutraPharma, Inc., with a 6% of gross revenue royalty arrangement or a minimum annual amount, whichever is greater, currently in place for NanoLogix.In addition, NanoLogix is presently operating a hydrogen bioreactor at Welch's Foods near Erie, Pennsylvania to produce hydrogen from Welch’s sugar-rich wastewater stream. Research and development into a next-generation commercial demonstration bioreactor for Welch’s is ongoing at Gannon University in Erie. This R&D effort has been solely funded by NanoLogix for the prototype bioreactor development, with major funding from Welch’s anticipated for the next stage. NanoLogix has signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation based upon NanoLogix's patents and designed to extract hydrogen from activated sewage sludge. The Company’s goal is to capitalize on the potential energy value of over 170 million tons of sewer sludge generated annually in the United States. NanoLogix plans to install the prototype in the Erie facility in the spring of 2008. NanoLogix has also filed 7 patents for its new BioNanoChannel™ Technology for rapid microorganism (bacteria/spores) detection and identification. This is a revolutionary, cutting-edge technology developed by Nanologix that enables the identification and/or growth of microorganism cultures in 1 to 7 hours. BioNanoChannel™ technology utilizes extremely small (5-15 microns in diameter, 0.04 nanoliters in volume) channels to trap microorganisms and then applies proprietary NanoLogix techniques covered in the patent applications to detect and/or identify the microorganisms in concentrations as small as a single cell. This technology is in sharp contrast to the traditional method for detection and growth utilizing Petri dishes --- a device invented in 1877 --- a process that normally takes 24 to 72 hours to identify or culture a microorganism. The importance of this is that in a critical infection situation, the ability to achieve rapid detection and identification of microorganisms can mean the difference between life and death. NanoLogix believes that BioNanoChannel™ technology has the potential to capture much of the current global multi-billion dollar Petri dish market. The company is currently in talks with the US Department of Defense for provision of BioNanoChannel technology to various government departments for use in the confirmation of the effectiveness of decontamination efforts in the event of biological attacks, currently specific to anthrax, but with the potential for use in the event of use of other biological agents or toxins. The company has been contacted by an international pharmaceutical company and asked to provide information and assistance in reducing the time to test pharmaceutical samples to less than 24 hours --- a task that is easily within the capabilities of the BioNanoChannel technology. NanoLogix is currently working with another firm to ascertain whether the company’s BioNanoChannel device can provide a method for reducing the time necessary for the identification and detection of protein markers that occur early on in victims of Traumatic Brain Injury (TBI). Although public attention has recently focused on TBI due to the publicity received by returning veterans from both Afghanistan and Iraq who have been exposed to various types of blast injuries from Improvised Explosive Devices (IED), in fact it is a condition that affects over 1,500,000 victims of accidents and violence each year in the United States alone. The research team’s initial findings have been positive. Earlier detection of these protein markers may lead to accelerated treatment and reduced long term negative effects on those who suffer from these potentially debilitating injuries.NanoLogix has the near-term potential to capitalize on their rapid-detection technology, as evidenced by recent and ongoing government and corporate interest. There is longer term potential for revenue from both the hydrogen bioreactor technology use in industrial and wastewater treatment plant settings, and in sales of medical and environmental test kit technology through NutraPharma. NanoLogix was founded as Infectech in 1989 by a research PhD and an MD. The company spent the next seventeen years performing research and development and filing and being granted various patents related primarily to medical test kit technology. During that period there was minimal focus on commercialization of the company’s growing portfolio of intellectual property. That changed in March of 2007, when a shareholder-led effort resulted in a change in executive management. The company is now run with a focus on the monetization of current intellectual property.